BCAL Diagnostics Limited (ASX:BDX)

Market Cap	25.81M +6.8%
Revenue (ttm)	2.35M -11.2%
Net Income	-7.37M
EPS	-0.02
Shares Out	368.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	265,690
Open	0.0770
Previous Close	0.0700
Day's Range	0.0770 - 0.0860
52-Week Range	0.0520 - 0.1550
Beta	0.81
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 3, 2026

About BCAL Diagnostics

BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2010
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BDX

Financial Performance

In fiscal year 2026, BCAL Diagnostics's revenue was 2.35 million, a decrease of -11.25% compared to the previous year's 2.65 million. Losses were -7.37 million, 1.80% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 17, 2026

Data Sources Report a data error